A Phase 3 interventional study of Pegylated-interferon Alfa-2a and Ribavirin in Hepatitis C, Chronic, sponsored by Hoffmann-La Roche. Completed at 23 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-01-23.
Sponsored by Hoffmann-La Roche · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 83 studies testing peginterferon alfa-2a in Hepatitis C, Chronic — none open to participants now, none under way, none of them phase 3. peginterferon alfa-2a · Hepatitis C, Chronic.
Among the 83 studies testing peginterferon alfa-2a in Hepatitis C, Chronic, this one is the 27th largest by enrollment, is one of 10 that started in 2007, is one of 19 in phase 3, and was the 30th registered.
950 studies on the registry are indexed under Hepatitis C, Chronic; 8 are open to participants now.
Browse Hepatitis C, Chronic studies →None of the 83 studies testing peginterferon alfa-2a in Hepatitis C, Chronic is open now. The open studies under Hepatitis C, Chronic, anywhere →
peginterferon alfa-2a: first FDA approval 2002 (PEGASYS), first EMA approval 2002. What it is approved for, and how studies give it, is on its page →
Of the 5 Hepatitis C, Chronic studies recruiting now, 2 set no upper age limit and 2 stop at 75 or younger; 1 takes children under 18; 1 takes healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
83 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 12 · Phase 3 20 · Phase 4 48
First in 2000; this study’s year is marked. 10 started in 2007.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 236 is above the median of 90 across 696 interventional studies indexed under Hepatitis C, Chronic.
Median enrollment 129 across the 83 interventional studies. Of the 75 that completed or were terminated, 38 (51%) have results posted.
This tab as a report to print or save as PDF → With an account.
44 of 83 have an industry lead sponsor. The 10 most frequent:
Hoffmann-La Roche is the lead sponsor of 2,102 studies on the registry; 89 are open to participants now.
Of its 330 completed or terminated interventional studies of FDA-regulated products, 248 (75%) have results posted.
86 studies in Hepatitis C, Chronic by Hoffmann-La Roche: none open now, none under way, none of them phase 3. Of 84 finished, 48 (57%) have results posted.
Among the 86 studies in Hepatitis C, Chronic by Hoffmann-La Roche, this one is the 22nd largest by enrollment of the 59 interventional ones that give a count, is one of 9 that started in 2007, is one of 9 in phase 3, and was the 20th registered.
Hoffmann-La Roche’s Hepatitis C, Chronic studies by the year they started, since 2001.
None of the studies under way reaches primary completion within a year.
Among the 83 studies testing peginterferon alfa-2a in Hepatitis C, Chronic, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Hoffmann-La Roche’s 86 in Hepatitis C, Chronic:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study will compare the efficacy and safety of treatment with pegylated-interferon alfa-2a plus ribavirin in participants with non-genotype 2/3 CHC who, after 12 weeks of study treatment, have undetectable hepatitis C virus (HCV)-ribonucleic acid (RNA) or a greater than or equal to (>=) 2 log10 drop in HCV-RNA. Participants will be randomized to receive pegylated-interferon alfa-2a 180 micrograms subcutaneously weekly plus ribavirin (1000-1400 milligram [mg]) orally daily for the specified duration, followed by 24 weeks of treatment-free follow-up. Participants with detectable HCV-RNA and less than (\<) 2 log10 drop in HCV-RNA at week 12 will discontinue therapy.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants with HCV RNA levels greater than (\>) 15 international units per milliliter (IU/mL) at Week 4, HCV RNA greater than or equal to (\>=) 15 IU/mL at Week 8, and either HCV RNA less than (\<) 15 IU/mL or \>=2 times logarithmic (2 log10) drop at Week 12, will receive pegylated-interferon alfa-2a (Pegasys) 180 micrograms (mcg) subcutaneously once in a week for 48 weeks, and ribavirin 1000 to 1400 milligrams (mg) orally daily for 48 weeks.
Drug: Pegylated-interferon Alfa-2a · Drug: Ribavirin
Participants with HCV RNA levels \>15 IU/mL at Week 4, HCV RNA \>=15 IU/mL at Week 8, and either HCV RNA \<15 IU/mL or \>=2 log10 drop at Week 12, will receive pegylated-interferon alfa-2a 180 mcg subcutaneously once in a week for 72 weeks, and ribavirin 1000 to 1400 mg orally daily for 72 weeks.
Drug: Pegylated-interferon Alfa-2a · Drug: Ribavirin
Participants with HCV-RNA levels \>15 IU/mL at Week 4, and HCV-RNA \<15 IU/mL at Week 8, will receive pegylated-interferon alfa-2a 180 mcg subcutaneously once in a week for 36 weeks, and ribavirin 1000 to 1400 mg orally daily for 36 weeks.
Drug: Pegylated-interferon Alfa-2a · Drug: Ribavirin
Participants with HCV-RNA levels \>15 IU/mL at Week 4, and HCV-RNA \<15 IU/mL at Week 8, will receive pegylated-interferon alfa-2a 180 mcg subcutaneously once in a week for 48 weeks, and ribavirin 1000 to 1400 mg orally daily for 48 weeks.
Drug: Pegylated-interferon Alfa-2a · Drug: Ribavirin
Participants with HCV-RNA levels \<15 IU/mL at Week 4, will receive pegylated-interferon alfa-2a 180 mcg subcutaneously once in a week for 24 weeks, and ribavirin 1000 to 1400 mg orally daily for 24 weeks.
Drug: Pegylated-interferon Alfa-2a · Drug: Ribavirin
Participants with HCV-RNA levels \<15 IU/mL at Week 4, will receive pegylated-interferon alfa-2a 180 mcg subcutaneously once in a week for 48 weeks, and ribavirin 1000 to 1400 mg orally daily for 48 weeks.
Drug: Pegylated-interferon Alfa-2a · Drug: Ribavirin
Participants who do not have any change in HCV-RNA levels at Weeks 4, 8, and 12 will not be randomized (NR) to any of the other groups. Participants will receive pegylated-interferon alfa-2a 180 mcg subcutaneously once in a week for 48 weeks, and ribavirin 1000 to 1400 mg orally daily for 48 weeks.
Drug: Pegylated-interferon Alfa-2a · Drug: Ribavirin
Participants will receive pegylated-interferon alfa-2a 180 mcg subcutaneously once in a week for the specified duration.
Also known as: Pegasys
Participants will receive ribavirin 1000 to 1400 mg orally daily for the specified duration.
Also known as: Copegus
Percentage of Participants With Sustained Virological Response (SVR) (Groups A and B)
SVR was defined as success if the participant had HCV RNA levels \<15 IU/mL as measured by COBAS AmpliPrep/COBAS TaqMan® HCV test at the 24-week untreated follow-up visit (HCV-RNA levels obtained at least 18 weeks after last dose of either pegylated-Interferon alfa-2a or ribavirin were considered if the 24-week untreated follow-up visit data were missing). Percentage of participants with SVR for Groups A and B was reported in this analysis.
Time frame: At 24-week untreated follow-up visit (up to 72 weeks for Group A, up to 96 weeks for Group B)
Percentage of Participants With SVR (Groups C, D, E, and F)
SVR was defined as success if the participant had HCV RNA levels \<15 IU/mL as measured by COBAS AmpliPrep/COBAS TaqMan® HCV test at the 24-week untreated follow-up visit (HCV-RNA levels obtained at least 18 weeks after last dose of either pegylated-Interferon alfa-2a or ribavirin were considered if the 24-week untreated follow-up visit data were missing). Percentage of participants with SVR for Groups C, D, E, and F was reported in this analysis.
Time frame: At 24-week untreated follow-up visit (up to 60, 72, 48, and 72 weeks for Groups C, D, E, and F, respectively)
Percentage of Participants With Virological Responses (Groups A, B, C, D, E, and F)
End of treatment response (ETR) was defined as "Success" if the HCV-RNA levels were \<15 IU/mL at the end of treatment. Early virological response (EVR) was defined as \>=2 log10 decrease in serum HCV RNA or undetectable serum HCV RNA (\<15 IU/mL) at Week 12. Complete EVR was defined as "Success", if the HCV-RNA levels were \<15 IU/mL at Week 12. Partial EVR was defined as "Success", if there was a \>=2 log10 drop in HCV-RNA at Week 12 compared to baseline but with a level that was still \>=15 IU/mL at that time point.
Time frame: Week 12 (Groups C, D, E, and F), and end of treatment (Weeks 48, 72, 36, 48, 24, and 48 for Groups A, B, C, D, E, and F, respectively)
| Milestone | Pegylated-interferon Alfa-2a + Ribavirin (Group A) | Pegylated-interferon Alfa-2a + Ribavirin (Group B) | Pegylated-interferon Alfa-2a + Ribavirin (Group C) | Pegylated-interferon Alfa-2a + Ribavirin (Group D) | Pegylated-interferon Alfa-2a + Ribavirin (Group E) | Pegylated-interferon Alfa-2a + Ribavirin (Group F) | Pegylated-interferon Alfa-2a + Ribavirin (Group NR) |
|---|---|---|---|---|---|---|---|
| Started | 41 | 43 | 30 | 31 | 25 | 26 | 40 |
| Completed | 36 | 24 | 30 | 25 | 23 | 18 | 0 |
| Not completed | 5 | 19 | 0 | 6 | 2 | 8 | 40 |
| Withdrew: Protocol violation | 0 | 0 | 0 | 0 | 0 | 0 | 3 |
| Withdrew: Withdrawal by subject | 1 | 6 | 0 | 0 | 1 | 3 | 2 |
| Withdrew: Lost to follow-up | 1 | 2 | 0 | 2 | 1 | 1 | 3 |
| Withdrew: Death | 0 | 2 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Other | 3 | 9 | 0 | 4 | 0 | 4 | 32 |
SVR was defined as success if the participant had HCV RNA levels \<15 IU/mL as measured by COBAS AmpliPrep/COBAS TaqMan® HCV test at the 24-week untreated follow-up visit (HCV-RNA levels obtained at least 18 weeks after last dose of either pegylated-Interferon alfa-2a or ribavirin were considered if the 24-week untreated follow-up visit data were missing). Percentage of participants with SVR for Groups A and B was reported in this analysis.
| percentage of participants | Pegylated-interferon Alfa-2a + Ribavirin (Group A) | Pegylated-interferon Alfa-2a + Ribavirin (Group B) |
|---|---|---|
| Percentage of Participants With Sustained Virological Response (SVR) (Groups A and B) | 48.8 | 39.5 |
SVR was defined as success if the participant had HCV RNA levels \<15 IU/mL as measured by COBAS AmpliPrep/COBAS TaqMan® HCV test at the 24-week untreated follow-up visit (HCV-RNA levels obtained at least 18 weeks after last dose of either pegylated-Interferon alfa-2a or ribavirin were considered if the 24-week untreated follow-up visit data were missing). Percentage of participants with SVR for Groups C, D, E, and F was reported in this analysis.
| percentage of participants | Pegylated-interferon Alfa-2a + Ribavirin (Group C) | Pegylated-interferon Alfa-2a + Ribavirin (Group D) | Pegylated-interferon Alfa-2a + Ribavirin (Group E) | Pegylated-interferon Alfa-2a + Ribavirin (Group F) |
|---|---|---|---|---|
| Percentage of Participants With SVR (Groups C, D, E, and F) | 73.3 | 74.2 | 84.0 | 84.0 |
End of treatment response (ETR) was defined as "Success" if the HCV-RNA levels were \<15 IU/mL at the end of treatment. Early virological response (EVR) was defined as \>=2 log10 decrease in serum HCV RNA or undetectable serum HCV RNA (\<15 IU/mL) at Week 12. Complete EVR was defined as "Success", if the HCV-RNA levels were \<15 IU/mL at Week 12. Partial EVR was defined as "Success", if there was a \>=2 log10 drop in HCV-RNA at Week 12 compared to baseline but with a level that was still \>=15 IU/mL at that time point.
| percentage of participants | Pegylated-interferon Alfa-2a + Ribavirin (Group A) | Pegylated-interferon Alfa-2a + Ribavirin (Group B) | Pegylated-interferon Alfa-2a + Ribavirin (Group C) | Pegylated-interferon Alfa-2a + Ribavirin (Group D) | Pegylated-interferon Alfa-2a + Ribavirin (Group E) | Pegylated-interferon Alfa-2a + Ribavirin (Group F) |
|---|---|---|---|---|---|---|
| ETR | 80.5 | 76.7 | 96.7 | 90.3 | 92.0 | 100.0 |
| Complete EVR | 0 | 0 | 93.3 | 96.8 | 88.0 | 92.0 |
| Partial EVR | 0 | 0 | 0 | 3.2 | 0 | 0 |
Collected over Baseline up to 96 weeks. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Pegylated-interferon Alfa-2a + Ribavirin (Group A) | — | 4/41 (9.8%) | 39/41 (95.1%) |
| Pegylated-interferon Alfa-2a + Ribavirin (Group B) | — | 6/43 (14%) | 43/43 (100%) |
| Pegylated-interferon Alfa-2a + Ribavirin (Group C) | — | 5/30 (16.7%) | 30/30 (100%) |
| Pegylated-interferon Alfa-2a + Ribavirin (Group D) | — | 4/31 (12.9%) | 31/31 (100%) |
| Pegylated-interferon Alfa-2a + Ribavirin (Group E) | — | 0/25 (0%) | 25/25 (100%) |
| Pegylated-interferon Alfa-2a + Ribavirin (Group F) | — | 4/26 (15.4%) | 25/26 (96.2%) |
| Pegylated-interferon Alfa-2a + Ribavirin (Group NR) | — | 3/40 (7.5%) | 35/40 (87.5%) |
| Event | Pegylated-interferon Alfa-2a + Ribavirin (Group A) | Pegylated-interferon Alfa-2a + Ribavirin (Group B) | Pegylated-interferon Alfa-2a + Ribavirin (Group C) | Pegylated-interferon Alfa-2a + Ribavirin (Group D) | Pegylated-interferon Alfa-2a + Ribavirin (Group E) | Pegylated-interferon Alfa-2a + Ribavirin (Group F) | Pegylated-interferon Alfa-2a + Ribavirin (Group NR) |
|---|---|---|---|---|---|---|---|
| Pregnancy of partnerSocial circumstances | 0/41 | 0/43 | 2/30 | 0/31 | 0/25 | 0/26 | 0/40 |
| PancytopeniaBlood and lymphatic system disorders | 0/41 | 0/43 | 0/30 | 0/31 | 0/25 | 1/26 | 0/40 |
| CellulitisInfections and infestations | 0/41 | 0/43 | 0/30 | 0/31 | 0/25 | 1/26 | 0/40 |
| SyncopeNervous system disorders | 0/41 | 0/43 | 0/30 | 0/31 | 0/25 | 1/26 | 0/40 |
| Suicide attemptPsychiatric disorders | 0/41 | 0/43 | 0/30 | 1/31 | 0/25 | 1/26 | 0/40 |
| Abdominal painGastrointestinal disorders | 0/41 | 0/43 | 1/30 | 0/31 | 0/25 | 0/26 | 0/40 |
| CaecitisGastrointestinal disorders | 0/41 | 0/43 | 1/30 | 0/31 | 0/25 | 0/26 | 0/40 |
| Chest painGeneral disorders | 0/41 | 1/43 | 1/30 | 0/31 | 0/25 | 0/26 | 0/40 |
| Atrial fibrillationCardiac disorders | 0/41 | 0/43 | 0/30 | 1/31 | 0/25 | 0/26 | 0/40 |
| CholecystitisHepatobiliary disorders | 0/41 | 0/43 | 0/30 | 1/31 | 0/25 | 0/26 | 0/40 |
| Event | Pegylated-interferon Alfa-2a + Ribavirin (Group A) | Pegylated-interferon Alfa-2a + Ribavirin (Group B) | Pegylated-interferon Alfa-2a + Ribavirin (Group C) | Pegylated-interferon Alfa-2a + Ribavirin (Group D) | Pegylated-interferon Alfa-2a + Ribavirin (Group E) | Pegylated-interferon Alfa-2a + Ribavirin (Group F) | Pegylated-interferon Alfa-2a + Ribavirin (Group NR) |
|---|---|---|---|---|---|---|---|
| Flu-like symptoms (fever, chills, headache, aches/pains)General disorders | 37/41 | 32/43 | 23/30 | 24/31 | 16/25 | 21/26 | 28/40 |
| Skin (injection site reactions, rashes, pruritus)Skin and subcutaneous tissue disorders | 24/41 | 24/43 | 20/30 | 16/31 | 12/25 | 18/26 | 16/40 |
| Emotional/mental (depression, anxiety, irritability, forgetfulness, confusion, anger)Psychiatric disorders | 21/41 | 25/43 | 15/30 | 17/31 | 11/25 | 15/26 | 13/40 |
| FatigueGeneral disorders | 18/41 | 22/43 | 15/30 | 8/31 | 10/25 | 12/26 | 6/40 |
| InsomniaPsychiatric disorders | 16/41 | 18/43 | 10/30 | 6/31 | 4/25 | 11/26 | 13/40 |
| Gastrointestinal symptoms (diarrhea, bloating, gas)Gastrointestinal disorders | 14/41 | 9/43 | 12/30 | 11/31 | 1/25 | 6/26 | 4/40 |
| AnemiaBlood and lymphatic system disorders | 12/41 | 16/43 | 5/30 | 7/31 | 4/25 | 4/26 | 1/40 |
| NeutropeniaBlood and lymphatic system disorders | 9/41 | 9/43 | 8/30 | 3/31 | 6/25 | 9/26 | 1/40 |
| NauseaGastrointestinal disorders | 11/41 | 10/43 | 5/30 | 8/31 | 7/25 | 4/26 | 5/40 |
| AlopeciaSkin and subcutaneous tissue disorders | 4/41 | 9/43 | 8/30 | 1/31 | 4/25 | 4/26 | 0/40 |
The safety (SAF) population included participants who received at least one dose of study medication and had at least one post-baseline safety assessment.
| Age, Continuous(years) | Pegylated-interferon Alfa-2a + Ribavirin (Group A) | Pegylated-interferon Alfa-2a + Ribavirin (Group B) | Pegylated-interferon Alfa-2a + Ribavirin (Group C) | Pegylated-interferon Alfa-2a + Ribavirin (Group D) | Pegylated-interferon Alfa-2a + Ribavirin (Group E) | Pegylated-interferon Alfa-2a + Ribavirin (Group F) | Pegylated-interferon Alfa-2a + Ribavirin (Group NR) | Total |
|---|---|---|---|---|---|---|---|---|
| Mean | 50.9 ± 8.55 | 51.0 ± 7.39 | 48.7 ± 11.54 | 47.8 ± 9.16 | 47.0 ± 10.38 | 47.0 ± 9.76 | 51.7 ± 7.52 | 49.5 ± 9.13 |
| Gender(Participants) | Pegylated-interferon Alfa-2a + Ribavirin (Group A) | Pegylated-interferon Alfa-2a + Ribavirin (Group B) | Pegylated-interferon Alfa-2a + Ribavirin (Group C) | Pegylated-interferon Alfa-2a + Ribavirin (Group D) | Pegylated-interferon Alfa-2a + Ribavirin (Group E) | Pegylated-interferon Alfa-2a + Ribavirin (Group F) | Pegylated-interferon Alfa-2a + Ribavirin (Group NR) | Total |
|---|---|---|---|---|---|---|---|---|
| Female | 16 | 19 | 10 | 12 | 6 | 9 | 13 | 85 |
| Male | 25 | 24 | 20 | 19 | 19 | 17 | 27 | 151 |
The record gives a start of Jun 2007, a primary completion of May 2010 and a completion of May 2010. It does not say whether these dates are actual or estimated.
Results were first posted in Jan 2017, 6 years 8 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Peginterferon alfa-2a · Ribavirin